动物造模,人脐带间充质干细胞 Z-bio 2023-02-15 545

　　Objective To investigate the safety and efficacy of human umbilical cord mesenchymal stem cells (HUC-MSCs) in the treatment of lipopolysaccharide (LPS) - induced acute lung injury in mice.

　　Methods The safety of HUC-MSCs was evaluated by tumorigenicity test, hemolysis test in vitro and acute toxicity test. C57BL/6 male mice aged 6 to 8 weeks were used as experimental subjects to establish acute lung injury models by intranasal or intraperitoneal injection of LPS. HUC-MSCs were given 6 hours after modeling, and the treatment group was divided into tail vein injection group (5 × 107 cells/kg), atomization group (HUC-MSCs conditioned medium). The pathological results of lung tissue of mice in each group were observed 96 hours after modeling, and the number and classification of inflammatory cells in BALF of mice were observed by Rayleigh Giemsa staining.

　　Results HUC-MSCs had no tumorigenicity, obvious hemolytic reaction and acute toxicity. Compared with the control group, both of the two modeling methods had lung injury to a certain extent. The McGuigan score of lung tissue pathological section showed that the lung injury caused by intraperitoneal injection of LPS was more serious than that caused by nasal drip. Compared with the model group, the degree of lung tissue injury in the treatment group was significantly reduced, and the effect of the tail vein injection group was better than that of the atomization group. The number of macrophages in BALF was significantly increased (P<0 001)。

　　Conclusion The acute lung injury model induced by intraperitoneal injection of LPS is better than that induced by intranasal administration. Injection of human umbilical cord mesenchymal stem cells into the tail vein can effectively treat acute lung injury in mice, and nebulization of HUC-MSCs conditioned medium can alleviate lung inflammation in mice.